Skip to main content

PHASE Scientific Donates 600 of its INDICAID COVID-19 Rapid Antigen At-Home Tests for CancerCon in Minneapolis June 9-12

News

May 20, 2022

PHASE Scientific Donates 600 of its INDICAID COVID-19 Rapid Antigen At-Home Tests for CancerCon in Minneapolis June 9-12

PHASE Scientific Americas (PHASE Scientific), a high-growth biotech company founded by bioengineers from UCLA, announces that it has donated 600 of its approved INDICAID COVID-19 2-pack Rapid Antigen At-Home Test (INDICAID OTC) to Stupid Cancer, Inc., a 501(c)3 nonprofit leader in the adolescent and young adult cancer movement for their annual CancerCon® event June 9-12 at Hyatt Regency in Minneapolis, MN.

 

CancerCon (#CCL22) is the premiere gathering for the adolescent and young adult cancer community. Each year, Stupid Cancer brings together hundreds of patients, survivors, advocates and health professionals to learn, share, and build community.

 

“Protecting the health of CancerCon participants is a top concern for the upcoming weekend,” explains Alison Silberman, CEO of Stupid Cancer.

 

 

“Our attendees include those who are at higher risk for the more severe forms of COVID-19, so we wanted to make it as easy as possible for all involved to test themselves before engaging with others on-site. PHASE Scientific’s INDICAID Rapid Antigen test is perfect tool for that purpose. We’re very grateful to PHASE Scientific for generously donating tests that we can share with all participants this year.”

 

 

 

“We are honored to support Stupid Cancer during this important event,” said Doug Field, Chief Revenue Officer of PHASE Scientific Americas. “We believe that proactive, over-the-counter diagnostic testing – in concert with point-of-care healthcare provider testing – is an essential element in combatting the spread of COVID-19. It is an especially important precaution for protecting COVID-vulnerable populations.”

 

For more information, please visit: https://stupidcancer.org/.

 

Read the Press Release at: Metro Atlanta CEO

 

 


 

 

More Related News